Is the Use of SGLT-2 Associated with an Increased Risk of Cancer?

Md Sadique Hussain; Gyas Khan; Gaurav Gupta

doi:10.2174/0115680096383119250307083130

ISSN: 1568-0096
E-ISSN: 1873-5576

HTML

f Is the Use of SGLT-2 Associated with an Increased Risk of Cancer?
Authors: Md Sadique Hussain¹, Gyas Khan² and Gaurav Gupta^3,4
View Affiliations Hide Affiliations

¹ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehradun 248007, Uttarakhand, India ; ² Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia ; ³ Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India; ⁴ Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, UAE
Source: Current Cancer Drug Targets, Volume 25, Issue 8, Aug 2025, p. 871 - 873
DOI: https://doi.org/10.2174/0115680096383119250307083130
- Received: 03 Jan 2025
- Accepted: 28 Jan 2025
- Available online: 17 Mar 2025

Preview this article:

There is no abstract available.

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096383119250307083130

2025-03-17

2025-12-17

From This Site

/content/journals/ccdt/10.2174/0115680096383119250307083130

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/deliver/fulltext/ccdt/25/8/CCDT-25-8-01.html?itemId=/content/journals/ccdt/10.2174/0115680096383119250307083130&mimeType=html&fmt=ahah

References

BahlG. UpadhyayD.K. VarmaM. SinghR. DasS. HussainS. Persistent chronic calcific pancreatitis with intraductal calculi associated with secondary diabetes mellitus type 3 and diabetic ketoacidosis – A case report.Endocr. Regul.202458110110410.2478/enr‑2024‑001138656253
[Google Scholar]
ChakrabartiK. McCuneW.J. SGLT-2 inhibitors: New horizons for rheumatologists.Curr. Opin. Rheumatol.202436535135910.1097/BOR.000000000000103039007236
[Google Scholar]
NaeimzadehY. TajbakhshA. NematiM. FallahiJ. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies.Eur. J. Pharmacol.202497817680310.1016/j.ejphar.2024.17680338950839
[Google Scholar]
PtaszynskaA. CohenS.M. MessingE.M. ReillyT.P. JohnssonE. JohnssonK. Assessing bladder cancer risk in type 2 diabetes clinical trials: The dapagliflozin drug development program as a ‘case study’.Diabetes Ther.20156335737510.1007/s13300‑015‑0128‑926323372
[Google Scholar]
BurkiT.K. FDA rejects novel diabetes drug over safety fears.Lancet2012379981550710.1016/S0140‑6736(12)60216‑522334883
[Google Scholar]
SalvatoreT. GalieroR. CaturanoA. RinaldiL. Di MartinoA. AlbaneseG. Di SalvoJ. EpifaniR. MarfellaR. DocimoG. LettieriM. SarduC. SassoF.C. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors.Int. J. Mol. Sci.2022237365110.3390/ijms2307365135409011
[Google Scholar]
DutkaM. BobińskiR. FrancuzT. GarczorzW. ZimmerK. IlczakT. ĆwiertniaM. HajdugaM.B. SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives.Cancers20221423581110.3390/cancers1423581136497303
[Google Scholar]
ReillyT.P. GrazianoM.J. JanovitzE.B. DorrT.E. FairchildC. LeeF. ChenJ. WongT. WhaleyJ.M. TirmensteinM. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Diabetes Ther.201451739610.1007/s13300‑014‑0053‑324474422
[Google Scholar]
StottlemyerB.A. McDermottM.C. MinogueM.R. GrayM.P. BoyceR.D. Kane-GillS.L. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: A pharmacovigilance study.Ther. Adv. Drug Saf.2023142042098623118133410.1177/2042098623118133437332887
[Google Scholar]
De JongheS. ProctorJ. VinkenP. FeyenB. WynantI. MarienD. GeysH. MamidiR.N.V.S. JohnsonM.D. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.Chem. Biol. Interact.201422411210.1016/j.cbi.2014.09.01825289773
[Google Scholar]
De JongheS. JohnsonM.D. MamidiR.N.V.S. VinkenP. FeyenB. LammensG. ProctorJ. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.Chem. Biol. Interact.2017277859010.1016/j.cbi.2017.09.00828916336
[Google Scholar]
Ahad MirP.R.I.N.C.E. HussainM.S. Ahmad KhandayM. Mohi-ud-din, R.; Pottoo, F.H.; Hasssan Mir, R. Immunomodulatory roles of mesenchymal stem cell-derived extracellular vesicles: A promising therapeutic approach for autoimmune diseases.Curr. Stem Cell Res. Ther.20242010.2174/011574888X34178124121604413039757602
[Google Scholar]
TangH. DaiQ. ShiW. ZhaiS. SongY. HanJ. SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.Diabetologia201760101862187210.1007/s00125‑017‑4370‑828725912
[Google Scholar]
PelletierR. NgK. AlkabbaniW. LabibY. MouradN. GambleJ.M. Adverse events associated with sodium glucose co-transporter 2 inhibitors: An overview of quantitative systematic reviews.Ther. Adv. Drug Saf.202112204209862198913410.1177/204209862198913433552467
[Google Scholar]
ShiN. ShiY. XuJ. SiY. YangT. ZhangM. NgD.M. LiX. XieF. SGLT-2i and risk of malignancy in type 2 diabetes: A meta-analysis of randomized controlled trials.Front. Public Health2021966836810.3389/fpubh.2021.66836834164370
[Google Scholar]
ChungC.T. LakhaniI. ChouO.H.I. LeeT.T.L. DeeE.C. NgK. WongW.T. LiuT. LeeS. ZhangQ. CheungB.M.Y. TseG. ZhouJ. Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study.Cancer Med.20231211122991231510.1002/cam4.592737148547
[Google Scholar]
DicembriniI. NreuB. MannucciE. MonamiM. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: A meta‐analysis of randomized controlled trials.Diabetes Obes. Metab.20192181871187710.1111/dom.1374530972917
[Google Scholar]
SpiazziB.F. NaiboR.A. WayerbacherL.F. PiccoliG.F. FarenzenaL.P. LonderoT.M. da NatividadeG.R. ZoldanM. DegobiN.A.H. NichesM. LopesG. BoykoE.J. UtzschneiderK.M. ColpaniV. GerchmanF. Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials.Diabetes Res. Clin. Pract.202319811062110.1016/j.diabres.2023.11062136921905
[Google Scholar]
LiY.R. LiuC.H. SunW.C. FanP.Y. LiuF.H. ChenT.H. WuV.C.C. LinC. HsiaoC.C. The risk of bladder cancer in type 2 diabetes mellitus with combination therapy of SGLT-2 inhibitors and pioglitazone.J. Pers. Med.202111982810.3390/jpm1109082834575605
[Google Scholar]

/content/journals/ccdt/10.2174/0115680096383119250307083130

Article Type: Editorial

Keyword(s): Antidiabetic agents; canagliflozin; cancer risk; dapagliflozin; empagliflozin; randomized controlled trials

Most Cited Most Cited RSS feed

- Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
  
  Authors: Yong Lin, Ranxin Shi, Xia Wang and Han-Ming Shen
- The Role of Snail in EMT and Tumorigenesis
  
  Authors: Yifan Wang, Jian Shi, Kequn Chai, Xuhua Ying and Binhua P. Zhou
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
  
  Authors: Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
  
  Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
  
  Authors: Ziyad Binkhathlan and Afsaneh Lavasanifar
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
  
  Authors: M. Abal, J.M. Andreu and I. Barasoain
- Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  
  Authors: R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson and M.V. Seiden
- The Role of Fibroblast Growth Factors in Tumor Growth
  
  Authors: M. Korc and R. E. Friesel
- Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
  
  Authors: M. Thomson and M. Ali
- Oxidative Stress and Cancer: The Role of Nrf2
  
  Authors: Soraya Sajadimajd and Mozafar Khazaei
More Less

f Is the Use of SGLT-2 Associated with an Increased Risk of Cancer?

Most Read This Month

Most Cited Most Cited RSS feed